| Trial code |
Type of patients |
Trial design |
N.of patients |
Patientage, years |
Comparison |
Median FU, years |
| MRC |
cT2-4,any N |
Open,
randomized |
500 |
500 |
WW vs. GOS AA
(or BOx) until progression (M0
patients only) |
<11 |
| EORTC
30846 |
pN1-3 |
Open,
randomized |
234 |
71 (51-58) |
RT vs. RT+GOS (starting on day 1
of RT) for 3 years CPA oral for 28
days |
8.5 |
| EORTC
30891 |
T0-4 N0-2 M0 |
Open,
randomized |
985 |
73(52-81 |
WWvs.BUSCPAoral for14days
(or subcapsular Ox) until
progression |
7.8 |
| EPC
WW
subgroup |
Locally advanced:cT3-
4,any N or any T, N+ |
Double-blind
randomized |
657 |
67(38-93) |
BIC vs. placebo |
5.4 |
| |
Localised:cT1-2,N0 or
Nx |
Double-blind
randomized |
1627 |
67(38-93) |
BIC vs. placebo |
5.4 |
| SAKK
08/88 |
T0-4, N0-2, M0-1
(UICC 1982) |
Open,
randomized |
197 |
76(56-86) |
Immediate Ox vs. delayed Ox |
>5 |
GOS, goserelin 3.6 mg s.c. every 28 days; FLU, flutamide 250 mg oral three times daily; BIC, bicalutamide 150 mg once daily; BUS, buserelin 6.3 mg; CPA, cyproterone
acetate; WW, watchful waiting; AA, antiandrogen; BOx, bilateral orchidectomy |
